MedMira Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Hermes Hermes Chan
- Full Time Employees
- 52
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 155 Chain Lake Drive Halifax NS Canada B3S 1B3
- IPO Date
- Dec 1, 1999
- Website
- medmira.com
- Similar Companies
- Business
- MedMira Inc. (TSX-V: MIR) develops, manufactures, and markets rapid point-of-care diagnostic tests for infectious diseases, including HIV, hepatitis C, and other viral infections. The company offers Reveal, Multiplo, and Sure Check product lines, which utilize proprietary rapid horizontal flow technology for lab-accurate results in minutes using fingerstick whole blood, serum, plasma, or oral fluid samples; these tests target professional and consumer markets with features like built-in controls, disposable cartridges, and compatibility with desktop analyzers. Operations span North America, Europe, Asia, and select emerging markets, with headquarters in Halifax, Nova Scotia, Canada, where the company was founded in 1994. Subsidiaries include MedMira Laboratories for R&D and manufacturing. In late 2024, MedMira launched expanded Multiplo multiplex tests for simultaneous detection of multiple infections and formed a strategic distribution alliance with a major Asian healthcare partner to accelerate market penetration in high-prevalence regions. Recent funding included a CAD 5 million equity raise in Q3 2025 to support U.S. FDA submissions for next-generation HIV self-tests and production scaling.
Company News
MedMira Reports Third Quarter Results FY2026
MedMira Reports Second Quarter Results FY2025
MedMira Reports First Quarter Results FY2026
MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis
MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada
MedMira Reports Second Quarter Results FY2025
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
MedMira Reports Second Quarter Results FY2025
MedMira Announces Partnership with MediGroup Physician Services in the United States
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
MedMira Reports First Quarter Results FY2025
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
MedMira Announces the appointment of Vice President of Commercial Operations
MedMira Reports Third Quarter Results FY2024
MedMira Announces the Hire of Vice President of Business Development